Stocksigma LogoStocksigma Logo

Lupin Receives Tentative US FDA Approval for Novel Apixaban Oral Suspension

Lupin has received tentative approval from the US FDA on 28th Sep'26 for its New Drug Application for Apixaban Oral Suspension (1.25 mg/mL) under the

Lupin Receives Tentative US FDA Approval for Novel Apixaban Oral Suspension

Lupin Ltd 路 Press Release 路 28 Sept 2026, 2:41 pm

Lupin Receives Tentative US FDA Approval for Novel Apixaban Oral Suspension Lupin has received tentative approval from the US FDA on 28th Sep'26 for its New Drug Application for Apixaban Oral Suspension (1.25 mg/mL) under the 505(b)(2) pathway. The product represents a novel oral liquid formulation of apixaban鈥攖he active ingredient in Bristol Myers Squibb's Eliquis鈥攄esigned for adult anticoagulation patients facing difficulty swallowing tablets. Upon receipt of final approval, the drug will be manufactured at Lupin's Somerset facility in New Jersey, strengthening the company's differentiated product portfolio and US market presence.

Original exchange filing (PDF)

More announcements from Lupin Ltd

All Lupin Ltd announcements